Skip to Content
Merck
All Photos(1)

Key Documents

B7688

Sigma-Aldrich

PiB

≥98% (HPLC)

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H18N2O8
CAS Number:
Molecular Weight:
438.39
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to light brown

solubility

DMSO: 1-2 mg/mL (warmed)

storage temp.

2-8°C

SMILES string

O=C(C1=C2C(C3=CC=C24)=C(C(N(CC(OCC)=O)C3=O)=O)C=C1)N(CC(OCC)=O)C4=O

InChI

1S/C22H18N2O8/c1-3-31-15(25)9-23-19(27)11-5-7-13-18-14(8-6-12(17(11)18)20(23)28)22(30)24(21(13)29)10-16(26)32-4-2/h5-8H,3-4,9-10H2,1-2H3

InChI key

WNKQGFNIIHNGQM-UHFFFAOYSA-N

Biochem/physiol Actions

PiB is an inhibitor of the peptidylprolyl isomerase Pin-1. Inhibition of Pin-1 leads to destabilization of the transcription factor Nanog, which is required for maintenance of embryonic stem cell cultures.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Stephan Müller et al.
Scientific reports, 7(1), 1225-1225 (2017-04-30)
The relationship between body-mass index (BMI) and Alzheimer´s disease (AD) has been extensively investigated. However, BMI alterations in preclinical individuals with autosomal dominant AD (ADAD) have not yet been investigated. We analyzed cross-sectional data from 230 asymptomatic members of families
Inge M W Verberk et al.
Alzheimer's research & therapy, 12(1), 118-118 (2020-09-30)
Blood-based biomarkers for Alzheimer's disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta(1-42/1-40), glial fibrillary acidic protein (GFAP) and neurofilament light
Christopher M Lee et al.
Journal of Alzheimer's disease : JAD, 62(4), 1691-1702 (2018-04-05)
On target 18F-Flortaucipir (FTP) binding of Alzheimer's disease tau aggregates and off-target binding of melanocytes have been demonstrated with autoradiography. We aimed to investigate the hypothesis that if binding in choroid plexus (CP) is due to melanocytes, the signal would
Jun Ho Lee et al.
Frontiers in aging neuroscience, 10, 309-309 (2018-10-20)
Background: Given the barriers prohibiting the broader utilization of amyloid imaging and high screening failure rate in clinical trials, an easily available and valid screening method for identifying cognitively impaired patients with cerebral amyloid deposition is needed. Therefore, we developed
Nancy J Donovan et al.
Journal of Alzheimer's disease : JAD, 46(1), 63-73 (2015-02-24)
Even low levels of depressive symptoms are associated with an increased risk of cognitive decline in older adults without overt cognitive impairment (CN). Our objective was to examine whether very low, "subthreshold symptoms of depression" are associated with Alzheimer's disease

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service